دورية أكاديمية
Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
| العنوان: | Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis |
|---|---|
| المؤلفون: | Pasquale F. Innominato, Valérie Cailliez, Marc-Antoine Allard, Santiago Lopez-Ben, Alessandro Ferrero, Hugo Marques, Catherine Hubert, Felice Giuliante, Fernando Pereira, Esteban Cugat, Darius F. Mirza, Jose Costa-Maia, Alejandro Serrablo, Real Lapointe, Cristina Dopazo, Jose Tralhao, Gernot Kaiser, Jinn-Shiun Chen, Francisco Garcia-Borobia, Jean-Marc Regimbeau, Oleg Skipenko, Jen-Kou Lin, Christophe Laurent, Enrico Opocher, Yuichi Goto, Benoist Chibaudel, Aimery de Gramont, René Adam |
| المصدر: | Cancers, Vol 14, Iss 17, p 4340 (2022) |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | colorectal cancer, liver metastases, hepatectomy, neo-adjuvant chemotherapy, preoperative chemotherapy, onco-surgical approach, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Background: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 14174340 2072-6694 |
| العلاقة: | https://www.mdpi.com/2072-6694/14/17/4340Test; https://doaj.org/toc/2072-6694Test |
| DOI: | 10.3390/cancers14174340 |
| الوصول الحر: | https://doaj.org/article/8494ff40ce4c498daf605a2504a860eeTest |
| رقم الانضمام: | edsdoj.8494ff40ce4c498daf605a2504a860ee |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14174340 20726694 |
|---|---|
| DOI: | 10.3390/cancers14174340 |